Table 2.
Biochemical markers of inflammatory activity and endothelial activation.
| RA patients (n = 29) | Control group (n = 29) | P value | P adjusteda | |||
|---|---|---|---|---|---|---|
| Nv | Mean (SD) | Nv | Mean (SD) | |||
| ADMA, µmol/L | 29 | 0.77 (0.2) | 28 | 0.67 (0.18) | 0.056 | 0.154 |
| SDMA, µmol/L | 29 | 0.56 (0.16) | 26 | 0.62 (0.18) | 0.125 | 0.111 |
| ADMA/SDMA ratio | 29 | 1.46 (0.57) | 26 | 1.17 (0.47) | 0.045 | 0.100 |
| sVCAM-1, ng/mL | 29 | 744.18 (190.08) | 28 | 613.3 (148.4) | 0.002 | 0.048 |
| MCP-1, pg/mL | 29 | 395.8 (249.3) | 28 | 262.4 (90.73) | <0.001 | 0.047 |
| sE-selectin, ng/mL | 29 | 17.65 (8.67) | 28 | 12.45 (8.02) | 0.007 | 0.183 |
| vWf, % | 29 | 109.75 (48.6) | 27 | 73.73 (22.39) | <0.001 | 0.003 |
| Osteoprotegerin, pmol/L | 29 | 5.18 (1.36) | 28 | 4.01 (1.06) | <0.001 | 0.108 |
| Pentraxin-3, ng/mL | 29 | 0.74 (0.29) | 28 | 0.45 (0.17) | <0.001 | <0.001 |
| ESR, mm/h | 28 | 37.21 (27.44) | 29 | 6.58 (4.79) | <0.001 | <0.001 |
| hsCRP, mg/L | 29 | 15.26 (24.6) | 29 | 0.84 (0.71) | <0.001 | 0.006 |
| TNF-α, pg/mL | 29 | 2.55 (1.06) | 28 | 1.78 (1.07) | <0.001 | 0.003 |
| Interleukin-6, pg/mL | 29 | 8.48 (8.33) | 28 | 0.86 (0.41) | <0.001 | 0.001 |
Data are shown as unadjusted means (SD).
Abbreviations: Nv: valid cases; RA: rheumatoid arthritis; ADMA: asymmetric dimethyl-L-arginine; SDMA: symmetric dimethyl-L-arginine; sVCAM-1: soluble vascular cell adhesion molecule-1; MCP-1: monocyte chemotactic protein-1; sE-selectin: soluble E-selectin; vWF: von Willebrand factor; ESR: erythrocyte sedimentation rate; hsCRP: high-sensitivity C-reactive protein; TNF-α: tumor necrosis factor-α.
aage-sex adjusted P-value for the defining groups of patients in ANOVA (GLM models)—type III Sum of Squares (SS) was used.
‡ P < 0.05 versus control group, ¥ P < 0.05 versus RA patients with low disease activity in post-hoc analyses for adjusted ANOVA.